High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo.
Intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) has not been evaluated in the Republic of Congo since its implementation in 2006 and there is no published data on molecular markers of SP resistance among Plasmodium falciparum isolates from pregnant women. This first study in this country aimed to describe the prevalence of dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) point mutations and haplotypes in P. falciparum isolates collected from pregnant women with asymptomatic infection. From March 2012 to December 2013, pregnant women attending Madibou health centre (in Southern Brazzaville) for antenatal visits were enrolled in this study after obtaining their written informed consent. Blood samples were collected and P. falciparum infections were characterized using PCR. A total of 363 pregnant women were enrolled. P. falciparum infection was detected in 67 (18.4%) samples as their PCR amplification of dhfr and dhps genes yielded bands and all the PCR products were successfully digested. Out of these 67 isolates, 59 (88%), 57 (85%) and 53 (79.1%) carried 51I, 59R and 108N dhfr mutant alleles, respectively. The prevalence of dhps 436A, 437G and 540E mutations were 67.1% (45/67), 98.5% (66/67) and 55.2% (37/67), respectively. More than one-half of the isolates carried quintuple mutations, with highly resistant haplotype dhfr51I/59R/108N + dhps437G/540E detected in 33% (22/67) whereas 25% (17/67) were found to carry sextuple mutations. We observed significantly higher frequencies of triple dhps mutations 436A/437G/540E and quintuple mutations dhfr51I/59R/108N+dhps437G/540E in isolates from women who received IPTp-SP than those who did not. Overall, this study shows high prevalence rates of SP-associated resistance mutations in P. falciparum isolates collected from pregnant women. The presence of the dhps mutant allele 540E and the high prevalence of isolates carrying quintuple dhfr/dhps mutations are here reported for the first time in the Republic of Congo. The increasing prevalence of multiple mutant alleles observed in this study is alarming and may present a challenge for the future interventions including IPTp-SP in the country.
Fondation Congolaise pour la Recherche Médicale, Faculté des Sciences de la Santé (University Marien Ngouabi), Brazzaville, People's Republic of Congo. Electronic address: felixkoukouikila@yahoo.fr.
Felix
F
Koukouikila-Koussounda
Fondation Congolaise pour la Recherche Médicale, Faculté des Sciences de la Santé (University Marien Ngouabi), Brazzaville, People's Republic of Congo. Electronic address: info@fcrm-congo.com.
Damien
D
Bakoua
Fondation Congolaise pour la Recherche Médicale, Faculté des Sciences de la Santé (University Marien Ngouabi), Brazzaville, People's Republic of Congo. Electronic address: info@fcrm-congo.com.
Anna
A
Fesser
Fondation Congolaise pour la Recherche Médicale, Faculté des Sciences de la Santé (University Marien Ngouabi), Brazzaville, People's Republic of Congo. Electronic address: michael.kombo@yahoo.fr.
Michael
M
Nkombo
Fondation Congolaise pour la Recherche Médicale, Faculté des Sciences de la Santé (University Marien Ngouabi), Brazzaville, People's Republic of Congo. Electronic address: vjeannhey@yahoo.fr.
Christevy
C
Vouvoungui
Fondation Congolaise pour la Recherche Médicale, Faculté des Sciences de la Santé (University Marien Ngouabi), Brazzaville, People's Republic of Congo; Faculté des Sciences et Techniques, University Marien Ngouabi, Brazzaville, People's Republic of Congo; Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany. Electronic address: fntoumi@fcrm-congo.com.
Francine
F
Ntoumi
D000293:Adolescent; D000328:Adult; D000483:Alleles; D000962:Antimalarials / Q000494:pharmacology*; D003223:Congo / Q000453:epidemiology; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D006239:Haplotypes; D006801:Humans; D016778:Malaria, Falciparum / Q000453:epidemiology* / Q000469:parasitology*; D009154:Mutation; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics*; D011247:Pregnancy; D015995:Prevalence; D015800:Protozoan Proteins / Q000235:genetics; D011739:Pyrimethamine / Q000494:pharmacology*; D013413:Sulfadoxine / Q000494:pharmacology*; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics; D055815:Young Adult
D000962:Antimalarials; D004338:Drug Combinations; D015800:Protozoan Proteins; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D013762:Tetrahydrofolate Dehydrogenase; D011739:Pyrimethamine
Plasmodium falciparum; Pregnant women; Republic of Congo; Sulfadoxine–pyrimethamine resistance markers